Search results for " Muscarinic Antagonists"

showing 6 items of 6 documents

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life

2016

Marco Contoli,1 Paolo Solidoro,2 Fabiano Di Marco,3,4 Nicola Scichilone,5 Angelo Corsico,6 Fulvio Braido,7 Pierachille Santus4,8 1Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Cardiovascular and Thoracic Department, Città della Salute, Turin, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4Respiratory Unit, San Paolo Hospital, Milan, Italy; 5Department of Internal Medicine, Section of Pulmonology (DIBIMIS), University of Palermo, Palermo, Italy; 6Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 7Allergy and Respiratory Diseases Clinic, DIMI, University of G…

Time FactorsReviewdaily symptomsAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational HealthSeverity of Illness IndexPulmonary Disease Chronic Obstructive0302 clinical medicineBronchodilatorMedicine030212 general & internal medicineLungCOPDHealth PolicyTropaneLAMAGeneral MedicineBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeTolerabilityChronic inflammatory responsePublic HealthHumanPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyTime Factormedicine.drug_classBronchoconstrictionSocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease03 medical and health sciencesAclidinium bromideaclidiniumAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Bronchoconstriction; Bronchodilator Agents; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome; Tropanes; Quality of LifeInternal medicineSeverity of illnessAnticholinergicCOPDHumansAdverse effectBronchodilator Agentlcsh:RC705-779business.industryEnvironmental and Occupational HealthDaily symptomPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemRecovery of Functionmedicine.diseasequality of life030228 respiratory systemPhysical therapybusinessTropanesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

Early management of COPD: Where are we now and where do we go from here? a delphi consensus project

2019

Fabiano Di Marco,1 Piero Balbo,2 Francesco de Blasio,3 Vittorio Cardaci,4 Nunzio Crimi,5 Giuseppe Girbino,6 Girolamo Pelaia,7 Pietro Pirina,8 Pietro Roversi,9 Pierachille Santus,10,11 Nicola Scichilone,12 Alessandro Vatrella,13 Patrizio Pasqualetti,14 Mauro Carone15 1Department of Health Sciences, University of Milan, Respiratory Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2SC Malattie dell’Apparato Respiratorio, AOU Maggiore della Carità, Novara, Italy; 3Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center S.p.A. Private Hospital, Department of Medicine and Health Sciences “V Tiberio”, University of Molise, Campobasso, It…

Adrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinedrug combinationspractice guidelines as topicConsensuPredictive Value of Testbronchodilator therapy; dyspnea; italy; respiratory symptoms; adrenal cortex hormones; adrenergic beta-2 receptor agonists; adult; bronchodilator agents; consensus; delphi technique; drug combinations; early diagnosis; early medical intervention; evidence-based medicine; female; humans; italy; male; middle aged; muscarinic antagonists; practice guidelines as topic; predictive value of tests; pulmonary disease; chronic obstructive; surveys and questionnaires; treatment outcomeadrenal cortex hormonesSettore MED/10 - Malattie Dell'Apparato RespiratorioInternational Journal of Chronic Obstructive Pulmonary DiseasedyspnoeaAdrenal Cortex HormonePulmonary Disease Chronic ObstructivemaleDrug CombinationEarly Diagnosiitalymiddle agedSurveys and Questionnairehumansmuscarinic antagonistsBronchodilator AgentOriginal Researchearly medical interventionpulmonary diseaselcsh:RC705-779chronic obstructiveHealth Policyadultbronchodilator agentsEnvironmental and Occupational Healthrespiratory symptomsbronchodilator therapylcsh:Diseases of the respiratory systemdyspneaBronchodilator therapy; Dyspnea; Italy; Respiratory symptoms; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational Healthpredictive value of testsMuscarinic AntagonistfemaleconsensusRespiratory symptomsurveys and questionnairestreatment outcomePublic Healthdelphi techniqueadrenergic beta-2 receptor agonistsevidence-based medicineHumanearly diagnosis
researchProduct

Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases.

2013

While acetylcholine (ACh) and muscarinic receptors in the bladder are mainly known for their role in the regulation of smooth muscle contractility, in other tissues they are involved in tissue remodelling and promote cell growth and proliferation. In the present study we have used primary cultures of human detrusor smooth muscle cells (HDSMCs), in order to investigate the role of muscarinic receptors in HDSMC proliferation. Samples were obtained as discarded tissue from men >65 years undergoing radical cystectomy for bladder cancer and cut in pieces that were either immediately frozen or placed in culture medium for the cell culture establishment. HDSMCs were isolated from samples, propagat…

AtropineMalePyrrolidinesMessenger030232 urology & nephrologyGene ExpressionPhosphatidylinositol 3-Kinases0302 clinical medicineAged Atropine; pharmacology Benzofurans; pharmacology Carbachol; pharmacology Cell Proliferation Cells; Cultured Cholinergic Agonists; pharmacology Gene Expression Humans Male Mitogen-Activated Protein Kinases; metabolism Muscarinic Antagonists; pharmacology Myocytes; Smooth Muscle; metabolism Phosphatidylinositol 3-Kinases; metabolism Piperidines; pharmacology Pirenzepine; analogs /&/ derivatives/pharmacology Proto-Oncogene Proteins c-akt; metabolism Pyrrolidines; pharmacology RNA; Messenger; metabolism Receptors; Muscarinic; physiology Urinary Bladder; cytologyPiperidinesSmooth MuscleReceptorsMuscarinic acetylcholine receptor M5Muscarinic acetylcholine receptorCells CulturedCulturedMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2Smooth muscle contractionMuscarinic acetylcholine receptor M1Receptors Muscarinic030220 oncology & carcinogenesisMitogen-Activated Protein KinasesAcetylcholinemedicine.drugmedicine.medical_specialtyCarbacholCellsMyocytes Smooth MuscleUrinary BladderMuscarinic AntagonistsBiologyCholinergic Agonists03 medical and health sciencesInternal medicineMuscarinicmedicineHumansRNA MessengerAgedBenzofuransCell ProliferationPharmacologyMyocytesPirenzepineEndocrinologyphysiologycytologyRNACarbacholanalogs /&/ derivatives/pharmacologymetabolismProto-Oncogene Proteins c-aktPharmacological research
researchProduct

Effects of a structured educational intervention in moderate-to-severe elderly asthmatic subjects.

2019

Background: Adherence to inhaled drugs is linked to patients’ satisfaction with their device, and an incorrect use can negatively affect the outcomes of asthma treatment. We speculated that this is particularly true in elderly asthmatic subjects. Aim: We performed a national pre-post interventional multicentre study, enrolling moderate-to-severe asthmatic subjects aged ≥65 ​years treated with fixed inhaled combination drugs by dry powder inhaler (DPI) or pressurized metered dose inhaler (pMDI). Adherence and critical errors were evaluated by means of validated questionnaires at first visit (V1) and after 3–6 months (V2). At V1, subjects underwent intensive training on the correct use of the…

Vital capacityACT asthma control testExacerbationSAE severe asthma exacerbationSF12chlorofluorocarbonsmental health composite scoreEDUCA elderly and device use in chronic asthmaPCS physical health composite scoreACT asthma control test; AHDS hospital anxiety depression scale; Asthma; CFC chlorofluorocarbons; Device misuse; EDUCA elderly and device use in chronic asthma; Education; Elderly; FEV1 forced expiratory volume 1s second; FVC forced vital capacity; ICS inhaled corticosteroids; LABA long-acting β2 agonist; LAMA long-acting muscarinic antagonists; MCS mental health composite score; PCS physical health composite score; PROs patient-reported outcomes; SAE severe asthma exacerbation; SF12 short form health survey; mMRC modified medical research councilEDUCAFEV10302 clinical medicineElderlyImmunology and AllergyMedicine030223 otorhinolaryngologybiologymMRC modified medical research councilsevere asthma exacerbationmodified medical research councilLAMASAELamaelderly and device use in chronic asthmaMetered-dose inhalerDry-powder inhalerDevice misusePROs patient-reported outcomesCFCPCSpatient-reported outcomesmMRClcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinelong-acting β2 agonistmedicine.medical_specialtyImmunologyLABAphysical health composite scoreArticleLAMA long-acting muscarinic antagonistsAHDSEducation03 medical and health sciencesFEV1/FVC ratiolong-acting muscarinic antagonistsforced vital capacitySF12 short form health surveyAsthma; Device misuse; Education; ElderlyInternal medicineMCS mental health composite scoreforced expiratory volume 1s secondAsthmabusiness.industryFEV1 forced expiratory volume 1s secondInhalerasthma control testbiology.organism_classificationmedicine.diseaseCFC chlorofluorocarbonsACTICS inhaled corticosteroidsFVCAsthmaMCShospital anxiety depression scale030228 respiratory systemICSAHDS hospital anxiety depression scaleFVC forced vital capacityPROsshort form health surveyinhaled corticosteroidslcsh:RC581-607businessLABA long-acting β2 agonistThe World Allergy Organization journal
researchProduct

Impact of long-term treatment with inhaled corticosteroids and bronchodilators on lung function in a patient with post-infectious bronchiolitis oblit…

2016

Post-infectious bronchiolitis obliterans (PIBO) is a small airways disease characterized by fixed airflow limitation. Therefore, inhaled bronchodilators and corticosteroids are not recommended as maintenance therapy options. The management of PIBO currently consists only of close monitoring of affected patients, aimed at the prevention and early treatment of pulmonary infections. In recent years, there has been an increase in the incidence of PIBO in the pediatric population. Patients with PIBO are characterized by a progressive decline in lung function, accompanied by a decrease in overall functional capacity. Here, we report the case of a relatively young man diagnosed with PIBO and follo…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyLong term treatmentmedicine.drug_classmedicine.medical_treatmentBronchiolitis obliteransInhaled corticosteroidsAnti-inflammatory agents/ therapeutic useCase ReportMuscarinic antagonists/therapeutic use03 medical and health sciences0302 clinical medicineAnti-inflammatory agents/therapeutic useBronchodilatormedicinePulmonary rehabilitation030212 general & internal medicineBronchiolitis obliterans/therapyLung functionGynecologylcsh:RC705-779Administration inhalationinhalationbusiness.industrylcsh:Diseases of the respiratory systemmedicine.diseaseAdministration inhalation; Adrenergic beta-2 receptor antagonists/therapeutic use; Anti-inflammatory agents/ therapeutic use; Bronchiolitis obliterans/therapy; Infection/complications; Lung diseases/rehabilitation; Muscarinic antagonists/therapeutic use; Pulmonary and Respiratory MedicineLung diseases/rehabilitation030228 respiratory systemPhysical performanceInfection/complicationAnesthesiaInfection/complicationsAdministrationbusinessAdrenergic beta-2 receptor antagonists/therapeutic usePediatric populationJornal Brasileiro de Pneumologia
researchProduct